US FDA appears to be embracing an increase in summarized Medical Device Reports from industry under the upcoming MDUFA IV user-fee agreement, while turning a cold shoulder to a more watered-down summary report requirement found in a decade-old congressional act.
Laid bare in an August draft Medical Device User Fee Amendment IV commitment letter, the agency will allow makers of a majority of devices to report adverse events...